Spinal Vascular Unit Breakdown as Universal Driver

Target: VEGFA Composite Score: 0.455 Price: $0.52▲5.2% Citation Quality: Pending neuroinflammation Status: active
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
5
Citations
1
Debates
5
Supporting
1
Opposing
Quality Report Card click to collapse
C
Composite: 0.455
Top 73% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C+ Mech. Plausibility 15% 0.50 Top 76%
C+ Evidence Strength 15% 0.50 Top 57%
C+ Novelty 12% 0.50 Top 82%
C+ Feasibility 12% 0.50 Top 65%
F Impact 12% 0.00 Top 50%
C+ Druggability 10% 0.50 Top 57%
C+ Safety Profile 8% 0.50 Top 57%
C+ Competition 6% 0.50 Top 77%
C+ Data Availability 5% 0.50 Top 71%
C+ Reproducibility 5% 0.50 Top 63%
Evidence
5 supporting | 1 opposing
Citation quality: 0%
Debates
1 session A
Avg quality: 0.86
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

Why do clinical manifestations overlap despite distinct underlying etiologies in immune-mediated myelopathies?

The abstract notes that clinical presentations overlap across different myelopathy etiologies, but the mechanistic basis for this convergent phenotype is not explained. Resolving this could improve differential diagnosis and reveal common therapeutic targets. Gap type: unexplained_observation Source paper: Uncommon inflammatory/immune-related myelopathies. (2021, J Neuroimmunol, PMID:34715593)

→ View full analysis & debate transcript

Description

Blood-spinal cord barrier breakdown represents mechanistic convergence point for diverse myelopathy etiologies, leading to stereotyped cascade of vascular dysfunction, protein extravasation, and secondary inflammation.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Diverse Spinal Cord Injury Triggers
ALS Trauma Ischemia Compression"] B["Spinal Vascular Unit Disruption
Blood-Spinal Cord Barrier Breakdown"] C["Pericyte Loss
Endothelial Tight Junction Degradation"] D["VEGFA Dysregulation
Pro-Angiogenic Signaling Imbalance"] E["Pathological Neovascularization
Leaky Immature Vessel Formation"] F["Serum Protein Extravasation
Complement Albumin Fibrinogen Influx"] G["Secondary Neuroinflammatory Cascade
Universal Spinal Cord Pathology"] H["Anti-VEGFA Combination Therapy
Bevacizumab or Aflibercept"] I["Vascular Stabilization
Pericyte Coverage Restored"] A --> B B --> C C --> D D --> E E --> F F --> G H -.->|"normalizes VEGFA"| D H --> I style D fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8 style I fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.50 (15%) Evidence 0.50 (15%) Novelty 0.50 (12%) Feasibility 0.50 (12%) Impact 0.00 (12%) Druggability 0.50 (10%) Safety 0.50 (8%) Competition 0.50 (6%) Data Avail. 0.50 (5%) Reproducible 0.50 (5%) KG Connect 0.50 (8%) 0.455 composite
6 citations 6 with PMID 5 medium Validation: 0% 5 supporting / 1 opposing
For (5)
5
No opposing evidence
(1) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
1
3
MECH 2CLIN 1GENE 3EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Biology and therapeutic targeting of vascular endo…SupportingGENENat Rev Mol Cel… MEDIUM2023-PMID:37491579-
Genome Editing VEGFA Prevents Corneal Neovasculari…SupportingGENEAdv Sci (Weinh) MEDIUM2024-PMID:38582513-
Herb-sourced emodin inhibits angiogenesis of breas…SupportingMECHTheranostics MEDIUM2020-PMID:32550907-
VEGFA mRNA-LNP promotes biliary epithelial cell-to…SupportingGENECell Stem Cell MEDIUM2023-PMID:38029740-
VEGFA/NRP-1/GAPVD1 axis promotes progression and c…SupportingCLINInt J Biol Sci MEDIUM2024-PMID:38169627-
No claimOpposingMECH- MODERATE2025-PMID:41488621-
Legacy Card View — expandable citation cards

Supporting Evidence 5

Biology and therapeutic targeting of vascular endothelial growth factor A. MEDIUM
Nat Rev Mol Cell Biol · 2023 · PMID:37491579
Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo. MEDIUM
Adv Sci (Weinh) · 2024 · PMID:38582513
Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription. MEDIUM
Theranostics · 2020 · PMID:32550907
VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases a… MEDIUM
VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis.
Cell Stem Cell · 2023 · PMID:38029740
VEGFA/NRP-1/GAPVD1 axis promotes progression and cancer stemness of triple-negative breast cancer by enhancing… MEDIUM
VEGFA/NRP-1/GAPVD1 axis promotes progression and cancer stemness of triple-negative breast cancer by enhancing tumor cell-macrophage crosstalk.
Int J Biol Sci · 2024 · PMID:38169627

Opposing Evidence 1

No claim MODERATE
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-09 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Based on the literature describing overlapping clinical presentations across different myelopathy etiologies despite distinct underlying causes, I'll generate novel therapeutic hypotheses that address this convergent phenotype through shared mechanistic pathways.

Hypothesis 1: Spinal Cord Microglia Activation State Convergence

Description: Despite different initial triggers (autoimmune, infectious, metabolic), all inflammatory myelopathies converge on a common microglial activation phenotype characterized by shared transcriptional programs. This convergence occurs through epigenetic re

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

I'll critically evaluate each hypothesis by examining the evidence base, identifying weaknesses, and proposing falsification experiments. Let me start with a systematic critique:

Hypothesis 1: Spinal Cord Microglia Activation State Convergence

Critical Weaknesses:
  • Oversimplified activation model: The hypothesis assumes microglia converge on a single "myelopathy-associated" state, but current evidence suggests context-dependent, heterogeneous activation profiles rather than binary states
  • Epigenetic assumption unsupported: No direct evidence provided for epigenetic reprogramm

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

PRACTICAL FEASIBILITY RANKING

Tier 1 (Immediately Feasible - Repurposing Opportunity)

  • S1P Pathway (Hypothesis 7): Fingolimod/siponimod already approved, safety known, could be tested in myelopathy populations within 2-3 years
  • Complement System (Hypothesis 3): Avacopan approved for vasculitis, eculizumab proven safe, strong mechanistic rationale
  • Tier 2 (Feasible with Significant Investment)

  • JAK/STAT3 (Hypothesis 5): Need CNS-penetrant compounds, but pathway validated
  • VEGF/Barrier (Hypothesis 2): Only if pursuing barrier-protective rather than inhibitory
  • Synthesizer Integrates perspectives and produces final ranked assessments

    Price History

    0.460.490.51 0.54 0.43 2026-04-212026-04-252026-04-28 Market PriceScoreevidencedebate 8 events
    7d Trend
    Stable
    7d Momentum
    ▲ 6.6%
    Volatility
    High
    0.0511
    Events (7d)
    7

    Clinical Trials (0)

    No clinical trials data available

    📚 Cited Papers (6)

    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet

    📅 Citation Freshness Audit

    Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

    No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

    📙 Related Wiki Pages (0)

    No wiki pages linked to this hypothesis yet.

    ࢐ Browse all wiki pages

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    📊 Resource Economics & ROI

    Moderate Efficiency Resource Efficiency Score
    0.50
    32.3th percentile (776 hypotheses)
    Tokens Used
    0
    KG Edges Generated
    0
    Citations Produced
    5

    Cost Ratios

    Cost per KG Edge
    0.00 tokens
    Lower is better (baseline: 2000)
    Cost per Citation
    0.00 tokens
    Lower is better (baseline: 1000)
    Cost per Score Point
    0.00 tokens
    Tokens / composite_score

    Score Impact

    Efficiency Boost to Composite
    +0.050
    10% weight of efficiency score
    Adjusted Composite
    0.505

    How Economics Pricing Works

    Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

    High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

    Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

    Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

    📋 Reviews View all →

    Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

    💬 Discussion

    No DepMap CRISPR Chronos data found for VEGFA.

    Run python3 scripts/backfill_hypothesis_depmap.py to populate.

    No curated ClinVar variants loaded for this hypothesis.

    Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

    🔍 Search ClinVar for VEGFA →
    Loading history…

    ⚖️ Governance History

    No governance decisions recorded for this hypothesis.

    Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

    Browse all governance decisions →

    KG Entities (29)

    C5AR1C5aC5aR1CX3CR1EIF2AK3ER stressER stress responseJAK/STAT3 signalingS1P gradient disruptionS1PR1STAT3VEGFAastrocyte activationastrocyte reactivityblood-spinal cord barrierblood-spinal cord barrier breakdowncomplement activationdemyelinationferroptosisglial scar formation

    Related Hypotheses

    IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microglia Interface
    Score: 0.831 | neuroinflammation
    STING Antagonists as ALS Therapeutics: Drug Repurposing
    Score: 0.771 | neuroinflammation
    Temporal SPP1 Inhibition During Critical Windows
    Score: 0.752 | neuroinflammation
    PDE4 Inhibition as Inflammatory Reset for PD Oligodendrocytes
    Score: 0.749 | neuroinflammation
    TREM2 Crosstalk and Synergistic Activation of Phagocytic Transcriptome
    Score: 0.740 | neuroinflammation

    Estimated Development

    Estimated Cost
    $0
    Timeline
    0 months

    🧪 Falsifiable Predictions

    No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

    Knowledge Subgraph (18 edges)

    activates (2)

    EIF2AK3ER stress responseC5aC5aR1

    causes (6)

    neuroinflammationmyelopathyferroptosisoligodendrocyte deathS1P gradient disruptionmyelopathyblood-spinal cord barrier breakdownvascular dysfunctioniron dysregulationferroptosis
    ▸ Show 1 more

    controls (1)

    S1PR1immune cell trafficking

    drives (2)

    complement activationneuroinflammationastrocyte activationglial scar formation

    enables (1)

    vascular permeabilityprotein extravasation

    increases (1)

    VEGFAvascular permeability

    maintains (2)

    S1PR1blood-spinal cord barrierCX3CR1microglial homeostasis

    mediates (2)

    C5AR1complement activationSTAT3astrocyte activation

    regulates (1)

    JAK/STAT3 signalingastrocyte reactivity

    Mechanism Pathway for VEGFA

    Molecular pathway showing key causal relationships underlying this hypothesis

    graph TD
        C5AR1["C5AR1"] -->|mediates| complement_activation["complement activation"]
        complement_activation_1["complement activation"] -->|drives| neuroinflammation["neuroinflammation"]
        neuroinflammation_2["neuroinflammation"] -->|causes| myelopathy["myelopathy"]
        S1PR1["S1PR1"] -->|controls| immune_cell_trafficking["immune cell trafficking"]
        S1PR1_3["S1PR1"] -->|maintains| blood_spinal_cord_barrier["blood-spinal cord barrier"]
        VEGFA["VEGFA"] -->|increases| vascular_permeability["vascular permeability"]
        vascular_permeability_4["vascular permeability"] -->|enables| protein_extravasation["protein extravasation"]
        STAT3["STAT3"] -->|mediates| astrocyte_activation["astrocyte activation"]
        astrocyte_activation_5["astrocyte activation"] -->|drives| glial_scar_formation["glial scar formation"]
        CX3CR1["CX3CR1"] -->|maintains| microglial_homeostasis["microglial homeostasis"]
        ferroptosis["ferroptosis"] -->|causes| oligodendrocyte_death["oligodendrocyte death"]
        EIF2AK3["EIF2AK3"] -->|activates| ER_stress_response["ER stress response"]
        style C5AR1 fill:#ce93d8,stroke:#333,color:#000
        style complement_activation fill:#81c784,stroke:#333,color:#000
        style complement_activation_1 fill:#81c784,stroke:#333,color:#000
        style neuroinflammation fill:#4fc3f7,stroke:#333,color:#000
        style neuroinflammation_2 fill:#4fc3f7,stroke:#333,color:#000
        style myelopathy fill:#ef5350,stroke:#333,color:#000
        style S1PR1 fill:#ce93d8,stroke:#333,color:#000
        style immune_cell_trafficking fill:#4fc3f7,stroke:#333,color:#000
        style S1PR1_3 fill:#ce93d8,stroke:#333,color:#000
        style blood_spinal_cord_barrier fill:#4fc3f7,stroke:#333,color:#000
        style VEGFA fill:#ce93d8,stroke:#333,color:#000
        style vascular_permeability fill:#4fc3f7,stroke:#333,color:#000
        style vascular_permeability_4 fill:#4fc3f7,stroke:#333,color:#000
        style protein_extravasation fill:#4fc3f7,stroke:#333,color:#000
        style STAT3 fill:#ce93d8,stroke:#333,color:#000
        style astrocyte_activation fill:#4fc3f7,stroke:#333,color:#000
        style astrocyte_activation_5 fill:#4fc3f7,stroke:#333,color:#000
        style glial_scar_formation fill:#4fc3f7,stroke:#333,color:#000
        style CX3CR1 fill:#ce93d8,stroke:#333,color:#000
        style microglial_homeostasis fill:#4fc3f7,stroke:#333,color:#000
        style ferroptosis fill:#4fc3f7,stroke:#333,color:#000
        style oligodendrocyte_death fill:#4fc3f7,stroke:#333,color:#000
        style EIF2AK3 fill:#ce93d8,stroke:#333,color:#000
        style ER_stress_response fill:#81c784,stroke:#333,color:#000

    3D Protein Structure

    🧬 VEGFA — Search for structure Click to search RCSB PDB
    🔍 Searching RCSB PDB for VEGFA structures...
    Querying Protein Data Bank API

    Source Analysis

    Why do clinical manifestations overlap despite distinct underlying etiologies in immune-mediated myelopathies?

    neuroinflammation | 2026-04-08 | completed

    Community Feedback

    0 0 upvotes · 0 downvotes
    💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

    No comments yet. Be the first to comment!

    View all feedback (JSON)

    Same Analysis (5)

    Spinal Cord Microglia Activation State Convergence
    Score: 0.46 · CX3CR1
    Sphingosine-1-Phosphate Gradient Disruption
    Score: 0.46 · S1PR1
    Oligodendrocyte Stress Response Uniformity
    Score: 0.46 · EIF2AK3
    Complement Cascade as Final Common Effector
    Score: 0.46 · C5AR1
    Spinal Cord Astrocyte Reactivity Convergence
    Score: 0.46 · STAT3
    → View all analysis hypotheses
    Public annotations (0)Annotate on Hypothes.is →
    No public annotations yet.